Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Initial phase 2 trial of a nicotinic agonist in schizophrenia.

Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR.

Am J Psychiatry. 2008 Aug;165(8):1040-7. doi: 10.1176/appi.ajp.2008.07071135. Epub 2008 Apr 1.

2.

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.

Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R.

Arch Gen Psychiatry. 2006 Jun;63(6):630-8.

PMID:
16754836
3.

Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.

Tregellas JR, Tanabe J, Rojas DC, Shatti S, Olincy A, Johnson L, Martin LF, Soti F, Kem WR, Leonard S, Freedman R.

Biol Psychiatry. 2011 Jan 1;69(1):7-11. doi: 10.1016/j.biopsych.2010.07.004. Epub 2010 Aug 21.

4.

α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.

Freedman R.

Annu Rev Med. 2014;65:245-61. doi: 10.1146/annurev-med-092112-142937. Epub 2013 Oct 9. Review.

PMID:
24111888
5.

Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia.

Tregellas JR, Olincy A, Johnson L, Tanabe J, Shatti S, Martin LF, Singel D, Du YP, Soti F, Kem WR, Freedman R.

Neuropsychopharmacology. 2010 Mar;35(4):938-42. doi: 10.1038/npp.2009.196. Epub 2009 Dec 2.

6.

DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats.

O'Neill HC, Rieger K, Kem WR, Stevens KE.

Psychopharmacology (Berl). 2003 Sep;169(3-4):332-9. Epub 2003 May 21.

PMID:
12759805
7.

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC.

Am J Psychiatry. 2008 Aug;165(8):1033-9. doi: 10.1176/appi.ajp.2008.06091591. Epub 2008 Jul 1.

PMID:
18593778
8.

Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice.

Simosky JK, Stevens KE, Kem WR, Freedman R.

Biol Psychiatry. 2001 Oct 1;50(7):493-500.

PMID:
11600102
9.

A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.

Buccafusco JJ, Terry AV Jr.

Biochem Pharmacol. 2009 Oct 1;78(7):852-62. doi: 10.1016/j.bcp.2009.06.102. Epub 2009 Jul 3.

10.

Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, Wonodi I, Buchanan RW, Myers C, Heishman SJ, Yang J, Nye A.

Arch Gen Psychiatry. 2011 Dec;68(12):1195-206. doi: 10.1001/archgenpsychiatry.2011.83. Epub 2011 Aug 1.

11.

Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Olincy A, Stevens KE.

Biochem Pharmacol. 2007 Oct 15;74(8):1192-201. Epub 2007 Jul 17. Review.

12.
13.

Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.

Olincy A, Freedman R.

Handb Exp Pharmacol. 2012;(213):211-32. doi: 10.1007/978-3-642-25758-2_8. Review.

14.

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Martin LF, Kem WR, Freedman R.

Psychopharmacology (Berl). 2004 Jun;174(1):54-64. Epub 2004 Feb 19. Review.

PMID:
15205879
15.

A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.

Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, Santarelli L.

Neuropsychopharmacology. 2014 Jun;39(7):1568-77. doi: 10.1038/npp.2014.17. Epub 2014 Jan 27.

16.

Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial.

Smith RC, Amiaz R, Si TM, Maayan L, Jin H, Boules S, Sershen H, Li C, Ren J, Liu Y, Youseff M, Lajtha A, Guidotti A, Weiser M, Davis JM.

PLoS One. 2016 Jan 5;11(1):e0143490. doi: 10.1371/journal.pone.0143490. eCollection 2016.

18.

DMXB (GTS-21) ameliorates the cognitive deficits in beta amyloid(25-35(-) ) injected mice through preventing the dysfunction of alpha7 nicotinic receptor.

Chen L, Wang H, Zhang Z, Li Z, He D, Sokabe M, Chen L.

J Neurosci Res. 2010 Jun;88(8):1784-94. doi: 10.1002/jnr.22345.

PMID:
20127813
19.

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.

Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, Lombardo I, Hilt DC.

Neuropsychopharmacology. 2015 Dec;40(13):3053-60. doi: 10.1038/npp.2015.176. Epub 2015 Jun 19.

20.

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.

Haig GM, Bain EE, Robieson WZ, Baker JD, Othman AA.

Am J Psychiatry. 2016 Aug 1;173(8):827-35. doi: 10.1176/appi.ajp.2015.15010093. Epub 2016 Mar 4.

PMID:
26940805

Supplemental Content

Support Center